SG11202006047RA - Small molecule modulators of pantothenate kinases - Google Patents
Small molecule modulators of pantothenate kinasesInfo
- Publication number
- SG11202006047RA SG11202006047RA SG11202006047RA SG11202006047RA SG11202006047RA SG 11202006047R A SG11202006047R A SG 11202006047RA SG 11202006047R A SG11202006047R A SG 11202006047RA SG 11202006047R A SG11202006047R A SG 11202006047RA SG 11202006047R A SG11202006047R A SG 11202006047RA
- Authority
- SG
- Singapore
- Prior art keywords
- small molecule
- molecule modulators
- pantothenate kinases
- pantothenate
- kinases
- Prior art date
Links
- 108010021592 Pantothenate kinase Proteins 0.000 title 1
- 102100024122 Pantothenate kinase 1 Human genes 0.000 title 1
- 150000003384 small molecules Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762610835P | 2017-12-27 | 2017-12-27 | |
PCT/US2018/067539 WO2019133635A1 (en) | 2017-12-27 | 2018-12-26 | Small molecule modulators of pantothenate kinases |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202006047RA true SG11202006047RA (en) | 2020-07-29 |
Family
ID=67068124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202006047RA SG11202006047RA (en) | 2017-12-27 | 2018-12-26 | Small molecule modulators of pantothenate kinases |
Country Status (12)
Country | Link |
---|---|
US (1) | US11891378B2 (pt) |
EP (1) | EP3731844A4 (pt) |
JP (1) | JP7352565B2 (pt) |
KR (1) | KR20200130242A (pt) |
CN (1) | CN111818922B (pt) |
AU (1) | AU2018395222B2 (pt) |
BR (1) | BR112020012875A2 (pt) |
CA (1) | CA3086671A1 (pt) |
IL (1) | IL275658B2 (pt) |
MX (1) | MX2020006754A (pt) |
SG (1) | SG11202006047RA (pt) |
WO (1) | WO2019133635A1 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11202006047RA (en) | 2017-12-27 | 2020-07-29 | St Jude Childrens Res Hospital Inc | Small molecule modulators of pantothenate kinases |
EP3731859A4 (en) | 2017-12-27 | 2021-09-22 | St. Jude Children's Research Hospital, Inc. | METHODS OF TREATMENT FOR DISORDERS ASSOCIATED WITH CASTOR |
WO2020198526A2 (en) * | 2019-03-27 | 2020-10-01 | St. Jude Children's Research Hospital | Small molecule modulators of pank |
WO2020203609A1 (ja) * | 2019-03-29 | 2020-10-08 | 日本ケミファ株式会社 | 掻痒を治療するためのt型カルシウムチャネル阻害剤の使用 |
JP2022081710A (ja) * | 2019-03-29 | 2022-06-01 | ユーティアイ リミテッド パートナーシップ | 関節リウマチを治療するためのt型カルシウムチャネル阻害剤の使用 |
WO2023230560A1 (en) * | 2022-05-26 | 2023-11-30 | Coa Therapeutics, Inc. | Treatment of organic acidemias or pantothenate kinase associated neurodegeneration with modulators of pantothenate kinases |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6894063B2 (en) | 2000-09-14 | 2005-05-17 | Schering Corporation | Substituted urea neuropeptide Y Y5 Receptor antagonists |
ES2329356T3 (es) | 2002-06-12 | 2009-11-25 | Chemocentryx, Inc. | Derivados de piperazina 1-arilo-4-sustituidos utilizados como antagonistas de ccr1 para el tratamiento de enfermedades inflamatorias e inmunitarias. |
US20050256130A1 (en) | 2002-06-12 | 2005-11-17 | Chemocentryx, Inc. | Substituted piperazines |
US7262194B2 (en) | 2002-07-26 | 2007-08-28 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
AR044688A1 (es) | 2003-06-12 | 2005-09-21 | Euro Celtique Sa | Agentes terapeuticos utiles para el tratamiento del dolor |
RU2006105716A (ru) | 2003-07-30 | 2007-09-10 | Зинон Фармасьютиклз Инк. (Ca) | Производные пиридазина и их применение в качестве терапевтических средств |
US7759348B2 (en) | 2003-07-30 | 2010-07-20 | Xenon Pharmaceuticals Inc. | Pyridazine derivatives and their use as therapeutic agents |
JP2007538106A (ja) | 2004-05-20 | 2007-12-27 | イーラン ファーマスーティカルズ、インコーポレイテッド | γセクレターゼのN−環式スルホンアミド阻害剤 |
US7754724B2 (en) | 2005-06-30 | 2010-07-13 | Dow Agrosciences Llc | N-substituted piperazines |
EP2089018A2 (en) | 2006-11-07 | 2009-08-19 | Lexicon Pharmaceuticals, Inc. | Methods of treating cognitive impairment and dementia |
WO2010115067A2 (en) | 2009-04-02 | 2010-10-07 | University Of Florida Research Foundation, Inc. | Engineering the pathway for succinate production |
CN101294194A (zh) * | 2007-04-28 | 2008-10-29 | 江苏先声药物研究有限公司 | 泛酸激酶药物筛选模型及其应用 |
US8153633B2 (en) | 2007-06-25 | 2012-04-10 | Amgen Inc. | Phthalazine compounds, compositions and methods of use |
DE102007035333A1 (de) | 2007-07-27 | 2009-01-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue substituierte Arylsulfonylglycine, deren Herstellung und deren Verwendung als Arzneimittel |
US20100041663A1 (en) | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
MX2012002532A (es) | 2009-09-01 | 2012-04-11 | Novozymes Inc | Metodos para mejorar la produccion de acido malico en hongos filamentosos. |
US9187772B2 (en) | 2010-09-01 | 2015-11-17 | University Of Florida Research Foundation, Inc. | L-malate production by metabolically engineered escherichia coli |
AU2011307304C1 (en) | 2010-09-27 | 2016-10-20 | Exelixis, Inc. | Dual inhibitors of MET and VEGF for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases |
WO2013004642A1 (en) | 2011-07-01 | 2013-01-10 | Remynd Nv | 1, 2, 4 -thiadiazol- 5 -ylpiperazine derivatives useful in the treatment neurodegenerative diseases |
US20130303509A1 (en) | 2012-05-11 | 2013-11-14 | Abbvie Inc. | Nampt inhibitors |
TW201444821A (zh) | 2013-03-13 | 2014-12-01 | Janssen Pharmaceutica Nv | 經取代之哌啶化合物及其作為食慾素受體調節劑之用途 |
EP3060570B1 (en) * | 2013-10-25 | 2018-09-19 | Retrophin, Inc. | Pantothenate derivatives for the treatment of neurological disorders |
AU2016249021A1 (en) | 2015-04-17 | 2017-10-19 | Assembly Biosciences, Inc. | Hepatitis B viral assembly effectors |
EP3474667A4 (en) | 2016-06-23 | 2019-11-27 | St. Jude Children's Research Hospital, Inc. | SMALL MOLECULAR MODULATORS OF PANTOTHENAT KINASES |
EP3731859A4 (en) | 2017-12-27 | 2021-09-22 | St. Jude Children's Research Hospital, Inc. | METHODS OF TREATMENT FOR DISORDERS ASSOCIATED WITH CASTOR |
SG11202006047RA (en) | 2017-12-27 | 2020-07-29 | St Jude Childrens Res Hospital Inc | Small molecule modulators of pantothenate kinases |
WO2019133634A1 (en) | 2017-12-27 | 2019-07-04 | St. Jude Children's Research Hospital | Small molecule modulators of pantothenate kinases |
WO2022133034A1 (en) | 2020-12-16 | 2022-06-23 | St. Jude Children's Research Hospital, Inc. | Methods of treating disorders associated with castor |
-
2018
- 2018-12-26 SG SG11202006047RA patent/SG11202006047RA/en unknown
- 2018-12-26 CA CA3086671A patent/CA3086671A1/en active Pending
- 2018-12-26 IL IL275658A patent/IL275658B2/en unknown
- 2018-12-26 MX MX2020006754A patent/MX2020006754A/es unknown
- 2018-12-26 KR KR1020207021837A patent/KR20200130242A/ko not_active Application Discontinuation
- 2018-12-26 EP EP18894179.3A patent/EP3731844A4/en active Pending
- 2018-12-26 AU AU2018395222A patent/AU2018395222B2/en active Active
- 2018-12-26 CN CN201880084571.4A patent/CN111818922B/zh active Active
- 2018-12-26 WO PCT/US2018/067539 patent/WO2019133635A1/en active Application Filing
- 2018-12-26 JP JP2020555731A patent/JP7352565B2/ja active Active
- 2018-12-26 US US16/958,022 patent/US11891378B2/en active Active
- 2018-12-26 BR BR112020012875-9A patent/BR112020012875A2/pt unknown
Also Published As
Publication number | Publication date |
---|---|
CN111818922B (zh) | 2023-06-13 |
CN111818922A (zh) | 2020-10-23 |
EP3731844A1 (en) | 2020-11-04 |
RU2020124599A (ru) | 2022-01-27 |
AU2018395222B2 (en) | 2023-06-08 |
WO2019133635A1 (en) | 2019-07-04 |
JP2021508739A (ja) | 2021-03-11 |
CA3086671A1 (en) | 2019-07-04 |
EP3731844A4 (en) | 2021-08-18 |
BR112020012875A2 (pt) | 2021-01-05 |
IL275658B2 (en) | 2024-04-01 |
US20210061788A1 (en) | 2021-03-04 |
KR20200130242A (ko) | 2020-11-18 |
US11891378B2 (en) | 2024-02-06 |
JP7352565B2 (ja) | 2023-09-28 |
AU2018395222A1 (en) | 2020-08-13 |
IL275658B1 (en) | 2023-12-01 |
MX2020006754A (es) | 2021-01-29 |
IL275658A (en) | 2020-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL283582A (en) | ror - gamma modulators | |
HK1256599A1 (zh) | ROR-γ的調節劑 | |
IL268820B (en) | Diaryl macrocycles as protein kinase modulators | |
IL263649B (en) | Small molecule modulators of pantothenate kinases | |
IL259342B (en) | Modulators of chemokine receptors | |
HK1250999A1 (zh) | Ror1-ror2結合的調節劑 | |
IL275658A (en) | Small molecule modulators of pantothenate kinases | |
GB201700711D0 (en) | Application of an optical effect | |
IL266261A (en) | ror-gamma modulators | |
GB201716468D0 (en) | Modulators | |
IL271359A (en) | Modulators of alpha-synuclein | |
IL274231A (en) | Modulators of ENAC expression | |
GB2563095B (en) | Modulators | |
IL271332B (en) | Tetrahydropyridopyrazine modulators of gpr6 | |
GB201702926D0 (en) | Modulators | |
GB201706043D0 (en) | Small molecules | |
GB201706042D0 (en) | Small molecules | |
EP3417064A4 (en) | KLK3 ACTIVATOR RNA MODULATORS |